Recent progress in drug delivery systems for tyrosine kinase inhibitors in the treatment of lung cancer.

Abstract excerpt

Lung cancer ranks as the second most commonly diagnosed cancer in both men and women worldwide. Despite the availability of diverse diagnostic and treatment strategies, it remains the leading cause of cancer-related deaths globally. The current treatment approaches for lung cancer involve the utilization of first generation (e.g., erlotinib, gefitinib) and second generation (e.g., afatinib) tyrosine kinase...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Delivery Systems
• Share to ErbB Receptors